The hepatitis C virus (HCV) infection may change the outcome of patients undergoing stem cell transplantation. This study aimed at determining the prevalence of the HCV antibody in patients who were alive 10 or more years after BMT, defining the annual progression rate of hepatic fibrosis in those patients, and identifying cases of cirrhosis among those who were positive for HCV antibody. Between 1979 and 1990, 259 patients had a bone marrow transplant, and 91 were alive in March 2000. Of those, 80 were included in the study after having been scanned for serum HCV antibodies. A total of 39 were positive (48.8%), one was indeterminate and 40 were negative (50%). The patients who were HCV positive or undetermined were called for a medical appointment and 22 (55%) attended. A total of 16 patients (72.7%) were male, the mean age was 37.879.2 years and all of them had had an allogeneic transplant. Of the 22 patients studied, 12 (54.5%) agreed to have a liver biopsy. Hepatic fibrosis was diagnosed in 10 patients. The hepatic fibrosis annual progression rate was 0.156 UF/year. Among the anti-HCV-positive patients assessed, three (13.6%) already had cirrhosis.
The identification of the hepatitis C virus (HCV) in 1989 made possible to recognize the virus, which was responsible for most post-transfusion non-A and non-B hepatitis (NANBH), 1 currently considered the major cause of chronic liver disease and indication for hepatic transplant in large centers. In Brazil, the hepatitis C test only became mandatory for blood donors in 1993. 2 The prevalence of HCV infection in patients who had had a BMT before screening varies from 4.8 to 70%. 3 The virus infection may change the natural history of those patients, in the shortterm, increasing the risk of serious venocclusive disease (VOD) of the liver and susceptibility to GVHD. With recovery of cellular immunity after transplantation, severe hepatitis and fulminant liver failure may occur. 4 In the long term, affected patients may develop an accelerated course of chronic liver disease leading to cirrhosis and to hepatocellular carcinoma (HCC) more rapidly than virus carriers who have not had a BMT. 4 Projections about these risks have been based on case reports and studies of patients with a survival rate of about 10 years, some of them significantly differing in regard to the importance of the HCV in the post-BMT. [4] [5] [6] [7] Today, with a worldwide BMT history of more than 30 years, hepatitis C in longterm survivors requires special attention. The aims of this study were: to determine the prevalence of the HCV antibody in patients who are alive 10 years or more after BMT at the Hospital de Clı´nicas of the Federal University of Parana´(HC-UFPR), to define the annual progression rate of hepatic fibrosis in those patients, and to detect liver cirrhosis among patients who are positive for the HCV antibody.
Patients and methods
The study included BMT patients from the HC-UFPR between 1979 and 1990, who were alive in March 2000 and were being followed at the outpatient clinic of the BMT Service. This study was approved by the Committee on Ethical Research in Human Beings of the HC-UFPR.
Data about screening for HCV antibodies were obtained from a review of patient charts. Patients had been screened for HCV antibodies by a second generation (Salck Indu´stria e Come´rcio de Produtos Biolo´gicos Ltda., Sa˜o Paulo, BR) or third generation (Abbott Laboratories, North Chicago, IL, USA) enzyme immunoassay (EIA) method. Samples that were positive at least twice were complemented by recombinant immunoblot assay (RIBA) (Chiron Corporation, Emeryville, CA, USA) or by the PCR technique (AMPLICOR kit -Roche Molecular Systems, Branchburg, NJ, USA). Positive or indeterminate anti-HCV patients were called for a medical appointment. Those who came between March 2000 and June 2001 answered a questionnaire that assessed risk factors for HCV contamination, history of alcohol intake, and which drugs they were taking at the time.
Percutaneous liver biopsy with a Menghini needle was performed in individuals positive by PCR who agreed to the procedure. The tissue obtained was fixed in formaldehyde solution at 10%, and submitted to routine histological analysis, the sections stained with hematoxylin and eosin, Schiff's periodic acid method, silver impregnation, Gomori trichrome, and Pearls' reaction. All material was analyzed by the same pathologist. Histological analysis focused on the portal inflammatory infiltrate, periportal necroinflamatory activity, parenchyma necroinflamatory activity, the stage of fibrosis, and steatosis and siderosis levels. Fibrosis staging was determined on a five-point scoring system: 0 ¼ normal lobe architecture, 1 ¼ fibrotic expansion involving portal spaces, 2 ¼ portal fibrotic expansion with portal-portal septa, 3 ¼ lobe architecture partially preserved, node traces, and 4 ¼ definite cirrhosis identified on biopsy, or predominance of node areas in remaining lobes. Diagnosis of liver cirrhosis was based on anatomopathological data (stage 4 fibrosis) or imaging methods (portal hypertension, chronic micronodular hepatopathy, and ascites). Annual fibrosis progression was defined as the ratio between the stage of fibrosis at biopsy and the estimated duration of infection in years, according to Poynard et al. 8 Time of infection was considered to be the difference between year of biopsy and year of BMT. For a descriptive analysis of the data, tables, charts, and graphs were used. 9 
Results
Between 1979 and 1990, 259 patients underwent BMT at the HC-UFPR, of which 112 were for aplastic anemia (AA), 26 for ALL, 58 for CML, 10 for Fanconi anemia, 40 for AML, and 13 for other conditions. Of the 91 patients who were alive in March 2000, 80 (87.9%) regularly returned to the hospital and had undergone hepatitis C serum testing. Of the three patients anti-HCV positive who died during the study, one died of spontaneous bacterial peritonitis as a complication of cirrhosis; one of tongue neoplasia; and one of congestive heart failure. A total of 39 patients (48.8%) tested HCV positive by EIA, one (1.2%) patient had an indeterminate EIA result, and 40 (50%) tested negative by EIA (Table 1 ). Of the 39 positive patients and the one indeterminate for anti-HCV, 31 were PCR positive (77.5%), and nine (22.5%) RIBA positive. Among those who were tested for viral RNA, 25 (80.6%) cases demonstrated viremia. All the patients (100%) having a RIBA assay tested positive. The BMT patient who had an indeterminate EIA result underwent PCR testing and tested positive ( Table 2 ).
In total, 22 anti-HCV-positive patients were seen during the study period and were examined to fulfill the second and third objectives: 16 (72.7%) were male and 6 (27.3%) female. The mean age in years was 37.879.2 years. Time between symptom onset and BMT was a median of 12 months -minimum 1 month and maximum 72 months. Most of the patients (76.2%) received cyclophosphamide as the conditioning agent. All had had an allogeneic BMT and had received an average of 207 transfused blood units or blood derivates while hospitalized in this Service. A review of post-BMT data disclosed information on acute and/or chronic GVHD in only 20 patient records. Five patients (25.0%) had acute GVHD, one of them with hepatic involvement. None of the patients had chronic GVHD. The median transaminase level before conditioning for BMT was 16 U/l for alanine transaminase (ALT) and 20 U/l for aspartate transaminase (AST). All patients who had been tested for HIV and hepatitis B surface antigen (HBsAg) were negative at the time (Table 3) .
When asked about alcohol intake, 13 (59.1%) patients gave positive answers, and due to the amount, three were considered at risk of hepatopathy.
Results obtained from supplementary analyses performed during the study period are shown in Table 4 . Five patients who were anti-HCV positive were also anti-HBc positive and one was HBsAg positive. Five patients had isolated anti-HBs positivity. One patient was positive for HIV. A total of 16 patients had an ultrasound of the upper abdomen and seven showed abnormalities. Two had a slightly heterogeneous parenchyma, three had hepatomegaly, one hepatoesplenomegaly, and one patient was reported to have portal hypertension, chronic micronodular hepatopathy, and ascites. Among these patients, only the one with portal hypertension did not have a liver biopsy. Transaminases and ferritin levels showed a very high standard deviation, and medians were used. In 17 (77.3%) patients, transaminases were above normal. ALT and AST values were 61.0 and 50.0 U/l, respectively, and the ferritin value was 502.83 ng/ml.
Concerning risk factors for HCV contamination, only one patient had used illicit drugs, and another had had hemodyalisis. Three patients reported to having worked in the health area.
A total of 12 (54.5%) patients underwent percutaneous hepatic biopsy (Table 5 ). All had viremia. Of the 22 patients studied, three (13.6%) had hepatic cirrhosis. In one, the diagnosis was confirmed by ultrasound, and all the other ones by histopathology.
In 19 patients, anti-smooth muscle, anti-mitochondria, anti-LKM, and antinuclear antibodies were titrated. Two patients tested positive (X1/80) for smooth muscle antibody, and one for anti-mitochondria antibody. Among the anti-HCV-positive patients on whom we had data concerning hepatic siderosis, alcohol intake, and autoantibodies (11 patients), the etiology of the hepatic pathology was as follows: HCV alone in two; HCV and hepatic siderosis in seven; HCV, alcohol intake, hepatic siderosis, and positive autoantibodies in two.
The profile of patients who had more advanced fibrosis (stages 3 and 4) showed 80% to be male, and older than the others at the time of BMT (30.077.1 years). They had a high alcohol intake (75%), portal and periportal inflammatory infiltrate stage 2, siderosis stage X2 (75%), and positive autoantibodies.
Among the patients in this study, the average fibrosis progression rate was 0.182 UF/year70.125, with a minimum value of 0 UF/year, maximum of 0.432 UF/year, and a median of 0.156 UF/year. It would take 25.6 years for the fibrosis to evolve into cirrhosis.
Discussion
Although the risk of acquiring HCV through blood and blood derivate transfusion has regressed, HCV infection will remain an important issue because some the infected subjects may be candidates for BMT or for marrow donation. In this study, there was a prevalence of HCV positive serology of 48.8% in a group of 80 patients who had had a BMT in Brazil before blood donors were screened. The numbers are higher than those reported in other studies. 4, 6, [10] [11] [12] [13] For example, 34% in USA, although the prevalence of HCV positivity in the general population is similar to Brazil nowadays. [14] [15] [16] This study infers that the prevalence found is higher than we had expected.
Among the 31 positive or indeterminate EIA patients studied by PCR for HCV, 80.6% had viremia, showing a good correlation between EIA and PCR in that population. However, Locasciulli et al 5 affirm there is little correlation between a positive EIA and viremia in BMT patients, possibly due to passive antibody transfer in transfusion, or to an immune response hampered by immunosuppression. According to the author, those results indicate the need to perform PCR in order to correctly identify HCV infection in BMT patients. 5 Other papers analyze the results of serological tests in BMT and immunocompromised patients. 10, 15, [17] [18] [19] [20] [21] [22] [23] Toma´s et al 23 found in a retrospective study of 61 BMT patients who had hepatic pathology, 29 patients with chronic hepatitis C of whom seven constantly tested anti-HCV negative but PCR positive. The Seattle group recommends hepatitis C testing, including viral RNA analysis. 21 In a study to assess HCV antibody formation in immunocompetent and immunodepressed patients (hemodialysis, kidney transplant, and BMT patients), the BMT group had more changes in reactivity to HCV antibodies during the period prior to recovery of humoral immunity, usually within 3 months after transplantation. During this phase, detection of anti-HCV alone is insufficient to provide a diagnosis. 19 On the other hand, Tada et al 18 found no HCV-RNA-positive patient who tested negative by a second generation EIA. Most likely, the BMT patients in their study were no longer immunosupressed. In another study, the same serum conversion rate for anti-HCV was found per blood unit transfused in BMT and immunocompetent patients. 24 Cornu, upon assessing the serum conversion time for anti-HCV in multitransfused and immunodepressed patients, found an interval in which the antibodies appeared, ranging between 4 months and 3 years after ALT increase. 17 Since the group of patients studied was considered to be immunocompetent while the study was being carried out, PCR was performed only in patients with positive or indeterminate EIA. The method used to detect anti-HCV, namely a second-or third-generation EIA, is believed to be adequate and sufficient to study the prevalence in BMT patients who are not immunosupressed.
Iron overload may be an important factor relating to liver disease in BMT patients. If GVHD and viral hepatitis are detected, a liver biopsy should be performed to correctly quantify the iron deposited in the liver. McKay et al 25 found high ferritin levels ranging between 139 and 5288 mg/l with a high median of 1312 mg/l in 88% of longterm BMT survivors. Toma´s et al 23 attributed the chronic hepatic pathology in BMT patients to iron overload in 52.4% of cases, whether or not it was associated to other factors such as hepatitis C. Among our patients, serum ferritin levels ranged from 10.0-2465.9 ng/ml with a median of 502.83 ng/ml. In 50% of them, ferritin levels were high. Hepatic siderosis was seen in 83% of biopsies.
In the present study, cirrhosis was presented in 13.6% of patients, and the annual fibrosis progression rate was 0.156 UF/year (median). A study carried out in nontransplanted patients, which used the same parameters, found a median of 0.133 UF/year, and estimated time of 30 years before infection developed into cirrhosis. 8 For the three cirrhotic patients, the average time between the BMT and development of cirrhosis was 13 years, which seems to be a rapid progression. Patients with a high alcohol intake may have effectively accelerated fibrosis progression. The fibrosis progression rate calculated for the whole group estimates the time between infection and cirrhosis as 25.64 years. Therefore, the progression rate found in this study is higher than that reported by Poynard et al 8 in nontransplanted patients.
Ljungman et al did not find cirrhosis in any patient biopsed after BMT in a 4-year follow-up, neither did they observe any signs of progressive severe liver disease. They concluded that HCV is not a major contributing factor to morbidity and mortality during the first 5-10 years after allogeneic BMT. 6 Toma´s et al
23
, with an average follow-up of 6 years, found no evidence of cirrhosis. Strasser et al, in a 10-year follow-up, observed that no patient who had survived for more than 5 years developed chronic liver failure or cirrhosis attributable to HCV. Between 3 and 10 years post-BMT, the survival curve for patients with or without hepatitis C was parallel, and mortality did not increase in positive patients. They concluded further that these data are in accordance with the natural history of hepatitis C in the first decade. 4 Most of the studies published assessed patients who had survived for approximately 10 years after BMT, and found no changes in morbidity and mortality in these patients. This study included exclusively patients who had been transplanted at least 10 years before, and found three cases of cirrhosis and one death due to liver complications. This outcome suggests that after a 10 years survival, HCV infection may begin to affect the morbidity and mortality of those patients. To prevent progression to cirrhosis, antiviral therapy with interferon-a plus oral ribavirin should be considered in any long-term survivor with chronic hepatitis C infection. The drugs can be safely administered to patients who have been off all immunosuppressive agents for at least 6 months and have no evidence of GVHD or myelosupression. 26 The author is treating such patients in this BMT Unit. The sustained virologic response rates observed was 60% and no significant adverse events were observed. 27 In summary, the prevalence of HCV antibody in patients who were alive 10 or more years after BMT at the HC-UFPR was 48.8% and the fibrosis annual progression rate was 0.156UF/year. Among the anti-HCV-positive patients assessed, three (13.6%) had cirrhosis.
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